Literature DB >> 19625381

A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury.

Rita Simone1, Renata Brizzolara, Alessandra Chiappori, Francesca Milintenda-Floriani, Clelia Natale, Luigi Greco, Mara Schiavo, Marcello Bagnasco, Giampaola Pesce, Daniele Saverino.   

Abstract

Celiac disease (CD) is a multifactorial disorder influenced by environmental, genetic and immunological factors. Increasing evidence showed CTLA-4 gene as an important susceptibility locus for autoimmune disorders. A native soluble cytotoxic T-lymphocyte-associated protein-4 (sCTLA-4), lacking of transmembrane sequence, has been described in several autoimmune diseases. We aimed to evaluate the presence of increased sCTLA-4 concentration in the serum of patients with CD and the possible immunoregulatory function. Blood samples were collected from 160 CD patients; sCTLA-4 levels were evaluated by ELISA, western blot and reverse transcription-PCR. The capability of serum sCTLA-4 to modulate T-lymphocyte proliferation in vitro was evaluated by two-way mixed leukocyte reaction assay. We demonstrated high levels of sCTLA-4 in serum of untreated celiac patients. Additionally, we observed that sCTLA-4 concentrations are related to gluten intake and that a correlation between autoantibodies to tissue transglutaminase and sCTLA-4 concentration exists. Moreover, sCTLA-4 levels correlate with the degree of mucosal damage. Conversely, no correlation between sCTLA4 levels and the HLA-related risk was observed. Finally, we show that sCTLA-4 from sera of CD patients displays functional activities. These results strongly suggest a regulation of sCTLA-4 synthesis depending on the presence or absence of dietary gluten and imply a possible immunomodulatory effect on cytotoxic T lymphocyte functions. In gluten-exposed patients, serum sCTLA-4 levels might provide insight about mucosal injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625381     DOI: 10.1093/intimm/dxp069

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

Review 1.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

2.  Correlation between systemic inflammatory response and quality of life in patients with chronic rhinosinusitis.

Authors:  Quinn Orb; Abigail Pulsipher; Kristine A Smith; Shaelene Ashby; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-18       Impact factor: 3.858

3.  Overexpression and secretion of the soluble CTLA-4 splice variant in various autoimmune diseases and in cases with overlapping autoimmunity.

Authors:  Suad AlFadhli
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-28

Review 4.  Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Authors:  Dario Camellino; Andrea Giusti; Giuseppe Girasole; Gerolamo Bianchi; Christian Dejaco
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

Review 5.  Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.

Authors:  Aaron Lerner; Carina Benzvi
Journal:  Biomedicines       Date:  2022-03-04

6.  The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses.

Authors:  Rita Simone; Giampaola Pesce; Princey Antola; Margarita Rumbullaku; Marcello Bagnasco; Nicola Bizzaro; Daniele Saverino
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

7.  Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles.

Authors:  Laura Esposito; Kara M D Hunter; Jan Clark; Daniel B Rainbow; Helen Stevens; Jennifer Denesha; Simon Duley; Sarah Dawson; Gillian Coleman; Sarah Nutland; Gwynneth L Bell; Carla Moran; Marcin Pekalski; John A Todd; Linda S Wicker
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

8.  Evaluation of HLA-DQ2/DQ8 genotype in patients with celiac disease hospitalised in 2012 at the Department of Paediatrics.

Authors:  Dorota A Szałowska-Woźniak; Leokadia Bąk-Romaniszyn; Agnieszka Cywińska-Bernas; Krzysztof Zeman
Journal:  Prz Gastroenterol       Date:  2014-03-01

9.  Significance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target.

Authors:  Candelaria Ponce de León; Pedro Lorite; Miguel Ángel López-Casado; Francisco Barro; Teresa Palomeque; María Isabel Torres
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

10.  A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression.

Authors:  Rita Simone; Claudya Tenca; Franco Fais; Matteo Luciani; Giulio De Rossi; Giampaola Pesce; Marcello Bagnasco; Daniele Saverino
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.